文献速递食管胃疾病与幽门螺杆菌

十日伏诺拉生-阿莫西林双联疗法作为幽门螺杆菌感染一线治疗与含铋四联疗法的比较

Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
PubMed 文献 · Am J Gastroenterol · 2022-12-02

该研究将375例初治幽门螺杆菌感染者按1:1:1随机分为VHA双联组、VA双联组和含铋四联组,比较10天方案的根除率、不良事件和依从性。VHA双联组根除率不劣于含铋四联组,且不良事件率显著更低;VA双联组未达到非劣效界值。

要点

  • VHA双联组根除率不劣于含铋四联组(P<0.001)。
  • 含铋四联组不良事件率显著高于VHA双联组(P=0.012)和VA双联组(P=0.001)。
  • 三组用药依从性无显著差异(P=0.995)。

核心结论

  • 10天VHA双联疗法作为幽门螺杆菌感染一线治疗,根除率>90%,不良事件率低于含铋四联疗法,依从性相似。
  • VA双联疗法的疗效不可接受。

研究设计与样本

  • 随机对照试验,共纳入375例初治幽门螺杆菌感染受试者,按1:1:1随机分为VHA双联组、VA双联组和含铋四联组。

主要发现

  • 符合方案分析根除率:含铋四联组90.9%,VHA双联组93.4%,VA双联组85.1%。
  • 改良意向性治疗分析根除率:含铋四联组89.4%,VHA双联组92.7%,VA双联组84.4%。
  • 意向性治疗分析根除率:含铋四联组88.0%,VHA双联组91.2%,VA双联组82.4%。
  • VHA双联组疗效不劣于含铋四联组(P<0.001),VA双联组未达到-10%的非劣效界值。
  • 含铋四联组不良事件率显著高于VHA双联组(P=0.012)和VA双联组(P=0.001);三组用药依从性无显著差异(P=0.995)。

关键数值与推荐

  • VHA双联方案:伏诺拉生20 mg每日2次+阿莫西林750 mg每日4次,疗程10天。
  • VA双联方案:伏诺拉生20 mg+阿莫西林1,000 mg每日2次,疗程10天。
  • 含铋四联方案:艾司奥美拉唑20 mg+铋剂200 mg+阿莫西林1,000 mg+克拉霉素500 mg每日2次,疗程10天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: No study has investigated the efficacy and safety of vonoprazan-amoxicillin dual therapy compared with bismuth quadruple therapy (B-quadruple). This study aimed to evaluate the efficacy and safety of 10-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with B-quadruple and to explore the optimal dosage of amoxicillin in the dual therapy. METHODS: A total of 375 treatment-naive, H. pylori -infected subjects were randomly assigned in a 1:1:1 ratio into 3 regimen groups including VHA-dual (vonoprazan 20 mg twice/day + amoxicillin 750 mg 4 times/day), VA-dual (vonoprazan 20 mg + amoxicillin 1,000 mg twice/day), and B-quadruple (esomeprazole 20 mg + bismuth 200 mg + amoxicillin 1,000 mg + clarithromycin 500 mg twice/day). Eradication rates, adverse events (AEs), and compliance were compared between 3 groups. RESULTS: The eradication rates of B-quadruple, VHA-dual, and VA-dual were 90.9%, 93.4%, and 85.1%, respectively, by per-protocol analysis; 89.4%, 92.7%, and 84.4%, respectively, by modified intention-to-treat analysis; 88.0%, 91.2%, and 82.4%, respectively, by intention-to-treat analysis. The efficacy of the VHA-dual group was not inferior to the B-quadruple group ( P < 0.001), but VA-dual did not reach a noninferiority margin of -10%. The AEs rates of the B-quadruple group were significantly higher than those of the VHA-dual ( P = 0.012) and VA-dual ( P = 0.001) groups. There was no significant difference in medication compliance among 3 treatment groups ( P = 0.995). CONCLUSIONS: The 10-day VHA-dual therapy provided satisfactory eradication rates of >90%, lower AEs rates, and similar adherence compared with B-quadruple therapy as a first-line therapy for H. pylori infection. However, the efficacy of VA-dual therapy was not acceptable.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Qian HS, Li WJ, Dang YN, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol. 2022. PMID: 36729890. doi:10.14309/ajg.0000000000002086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。